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Abstract: Pulmonary hypertension (PH) is a heterogeneous disorder associated with a poor prognosis.
Thus, the development of novel treatment strategies is of great interest. The enzyme arginase
(Arg) is emerging as important player in PH development. The aim of the current study was
to determine the expression of ArgI and ArgII as well as the effects of Arg inhibition in a rat
model of PH. PH was induced in 35 Sprague–Dawley rats by monocrotaline (MCT, 60 mg/kg
as single-dose). There were three experimental groups: sham-treated controls (control group,
n = 11), MCT-induced PH (MCT group, n = 11) and MCT-induced PH treated with the Arg inhibitor
Nω-hydroxy-nor-L-arginine (nor-NOHA; MCT/NorNoha group, n = 13). ArgI and ArgII expression
was determined by immunohistochemistry and Western blot. Right ventricular systolic pressure
(RVPsys) was measured and lung tissue remodeling was determined. Induction of PH resulted in
an increase in RVPsys (81 ± 16 mmHg) compared to the control group (41 ± 15 mmHg, p = 0.002)
accompanied by a significant elevation of histological sum-score (8.2 ± 2.4 in the MCT compared
to 1.6 ± 1.6 in the control group, p < 0.001). Both, ArgI and ArgII were relevantly expressed in lung
tissue and there was a significant increase in the MCT compared to the control group (p < 0.01). Arg
inhibition resulted in a significant reduction of RVPsys to 52 ± 19 mmHg (p = 0.006) and histological
sum-score to 5.8 ± 1.4 compared to the MCT group (p = 0.022). PH leads to increased expression
of Arg. Arg inhibition leads to reduction of RVPsys and diminished lung tissue remodeling and
therefore represents a potential treatment strategy in PH.
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1. Introduction
Pulmonary hypertension (PH) is a severe clinical condition associated not only with a reduced
quality of life but also with a markedly impaired prognosis. The term PH subsumes a heterogeneous
group of disorders resulting in an elevated pulmonary artery pressure (PAP) defined as a mean PAP
above 25 mmHg measured by right heart catheterization. The current guidelines describe five clinical
groups of PH differing in pathogenesis and especially in treatment options [1,2]. Whereas specific
treatment strategies exist for pulmonary arterial hypertension (PAH) and chronic thromboembolic
PH (CTEPH) by using prostanoids, endothelin receptor antagonists, phosphodiesterase inhibitors or
a soluble guanylate cyclase agonist (only approved treatment option for group 4 of PH = CTEPH),
therapy is limited to the treatment of the underlying disease and symptom control for the remaining
groups, especially PH due to left heart disease and PH due to pulmonary disease/hypoxia, [3]. In
either case, until now there are no curative treatment strategies to stop or even reverse the process of
pulmonary vascular remodeling which, together with vasoconstriction and thrombosis, are the main
pathophysiological building blocks of PH irrespective of the aetiology [4].
The main function of the enzyme arginase (Arg) is the conversion of l-arginine to l-ornithine and
urea [5,6]. As a result of this, Arg competes with nitric oxide (NO) synthase for their common substrate
l-arginine. By this mechanism, Arg plays an important role in the regulation of endothelial function
and vessel wall remodeling both in systemic and pulmonary hypertension. Thus, the enzyme is of great
interest as a potential therapeutic target to causally influence the development of PH [7]. Arg exists
in the two distinct isoforms Arg I and Arg II, which show species-specific differences both in tissue
distribution and cellular/subcellular localization. Both isoforms are induced by pathologic stimuli
such as hypoxia [6] and mediate several processes resulting in an impaired vascular cell function and
detrimental vessel wall remodeling, which, in the case of PH, leads to an elevated PAP [7–11]. The
induction and perpetuation of vessel wall remodeling by Arg is not limited to its reciprocal regulation
of NO formation but is also due to its capability to enhance proliferation of vascular smooth muscle
cells and endothelial cells [10,12–14]. Moreover, Arg stimulates synthesis and extracellular deposition
of collagen [15]. Taken together, the main effects of Arg I and Arg II are the mediation of proliferative,
fibrotic and inflammatory reactions within the complex process of vascular remodeling [7]. On the
other hand it is important to point out that the up-regulation of Arg is not restricted to cardiovascular
disorders but is also present in physiological processes like wound healing or as a constituent of the
urea cycle [16,17].
Previous studies have indicated a role of Arg I and Arg II in PH. Arg inhibition reduced
inflammation, airway remodeling and right ventricular hypertrophy in a guinea pig model of chronic
obstructive pulmonary disease [18]. Arg expression is increased and Arg inhibition prevents PAH
development in a rat model of PH induced by intermittent hypoxia suggesting a crucial pathological
role of the enzyme [19]. Human pulmonary artery smooth muscle cells could be evidenced to
be an important cell phenotype within the process of hypoxia-induced PH since Arg inhibition
significantly attenuated proliferative capacity in these cells [20]. Arg inhibition could also prevent
bleomycin-induced PH, vascular remodeling and collagen deposition in neonatal rats [21]. Another
interesting study in a rat model of monocrotaline-induced PH could show that deactivation of the
sympathetic nervous system by cervical ganglion block resulted in attenuation of the progression of
PH via the NO and Arg pathways [22]. In a very recent small human study in patients with PAH it
could be demonstrated that there is an increased breakdown of arginine by Arg affecting NO synthesis
compared to healthy controls. These findings highlight the role of Arg in PH development [23].
Further data on PH as a consequence of hemolysis due to the increased release of Arg 1 from damaged
erythrocytes speak well for a functional role of the enzyme in PH pathogeneses. This could be shown in
patients suffering from sickle cell disease or thalassemia as well. [24,25] Since two distinct Arg isoforms
exist, the question arises which isoform is of predominant functional relevance in PH development.
From recent studies the following is known: Both, Arg I and Arg II are up-regulated in mouse models
of hypoxia induced PH [26]. In the human system, Arg II but not Arg I was detected in pulmonary
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arterial endothelial cells [27]. Most studies reporting on the crucial role of Arg in PH development
in animal models, identified Arg II as the most relevant isoform [10,12,13,28–30]. In this context the
phenomenon of species specificity of Arg isoform expression must be taken into account [7]. Since
most studies have been performed in rodent animal models, there is a limited transferability of the
results into the human system.
There is growing evidence that pharmacological Arg inhibition [31] is a promising novel tool
to therapeutically intervene in disorders associated with PH development. A well established and
widely accepted animal model of PH is the rat model of monocrotaline-induced PH [32]. The majority
of preclinical studies on treatment of group 1 PH (PAH) have been performed using this model.
Despite several limitations of the model, there is no better alternative until now qualifying it as state
of the art in preclinical testing of novel agents for specific PH treatment [33]. Aims of the study: Our
current study was aimed to differentially investigate for the first time the structural changes in lung
tissue remodeling in the classical model of monocrotaline induced PH in relation to Arg isoform
expression and differential tissue distribution as well as to elucidate the effectiveness of non-selective
Arg inhibition as novel treatment approach in PH.
2. Results
2.1. Clinical and Haemodynamic Characterization of the Different Experimental Groups
Two of the 35 rats included in this study died throughout the experiments for unknown reasons.
These rats belonged to the MCT group. All the other 33 rats showed a continuous increase in body
weight but the level was different between the groups: control group (n = 11, mean weight increase
162 ± 26 g) > MCT/nor-NOHA group (n = 13, mean weight increase 111 ± 27 g) > MCT group (n = 9,
mean weight increase 89 ± 14 g). The comparison of the different groups including p-values is given
in Figure 1a. Clinical state of health of the animals was frequently assessed as described above (clinical
severity score). As depicted in Figure 1b, MCT treated rats had a reduced clinical state of health
compared to the control group, nor-NOHA treatment was associated with both improved weight
increase and higher clinical severity scores compared to the MCT group (Figure 1a,b).
Differential protein expression analysis of Arg I and Arg II in rat lung tissue of MCT induced
pulmonary hypertension.
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Figure 1. Graphical presentation of body weight increase (a) and clinical severity score (b) in the 
three experimental groups: control = sham-treated animals (n = 11); MCT = monocrotaline induced 
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Figure 1. Graphical presentation of body weight increase (a) and clinical severity score (b) in the three
experimental groups: control = sham-treated animals (n = 11); MCT = monocrotaline induced PH
(n = 11); MCT/nor-NOHA = monocrotaline induced PH treated with nor-NOHA (n = 13). Data are
presented as means and standard deviation (SD).
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2.2. Immunohistochemistry
Arg I and Arg II expression could be detected not only in diseased but also in healthy lung tissue.
As already known from a detailed analysis of Arg I und Arg II tissue expression in healthy rat organs
performed by Choi and co-workers in 2012 [34], both enzymes show a moderate expression in alveolar
macrophages. Arg I is additionally expressed in the epithelium of the bronchioles and the alveoli at a
moderate level. Arg II shows a weak expression in the epithelium of the bronchioles and a minimal
expression in the alveoli. These expression patterns could be, in general, confirmed also in the healthy
rat lung tissue obtained from our animal model. Moreover, especially for Arg II, we could find a weak
positivity of endothelial cells in peribronchial arteries, which has not been described before.
Arg I showed an increased expression and tissue deposition in diseased lung tissue of IPH rats
(MCT group) compared to healthy organs (control group) (Figure 2). There is an enhanced staining
positivity in the lung parenchyma and, especially, in the alveolar macrophages (Figure 2b, arrowheads
= alveolar macrophages). Moreover, endothelial cells of peribronchial arteries show a mild to moderate
positivity (Figure 2c, arrow) compared to healthy lung tissue (Figure 2a). The staining intensity of the
epithelium of the bronchioles is more or less equal to that occurring in normal tissue (Figure 2c, *).
Figure 2d shows the negative control for Arg I staining (Figure 2d).
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Figure 2. Arg I showed an increased expression and tissue deposition in induced pul onary
hypertension (IP ) rats (b–c) co pared to the controls (a) enhanced staining positivity in the lung
parenchy a and in alveolar acrophages ((b), arro heads = alveolar acrophages) and ild to
oderate positivity in endothelial cells of peribronchial arteries ((c), arro ); staining intensity of the
epitheliu of the bronchioles is ore or less equal to that occurring in nor al tissue ((c), *); negative
control for rg I staining ( ).
Arg II exhibited a distinct increase in expression and tissue deposition in diseased lung tissue
from IPH rats (MCT group) compared to healthy organs (control group) (Figure 3), in particular in the
lung parenchyma and the epithelium of the bronchioles (Figure 3b), the endothelium of peribronchial
arteries (Figure 3c) and in alveolar macrophages (Figure 3d). Figure 3e shows the negative control for
Arg I staining (Figure 3e).
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Figure 3. Arg II exhibited a distinct increase in expression and tissue deposition in IPH rats (b–d)
compared to controls ((a), * = bronchiolus) in particular in the lung parenchyma (**) and the epithelium
of the bronchioles (*) (b), the endothelium of peribronchial arteries ((c), arrow) and in alveolar
macrophages ((d), arrowheads = alveolar macrophages); negative control (e).
2.3. Western Blot Analysis
To confirm the expression of Arg protein including a semi-quantitative analysis, we performed
Western blot analysis of Arg I and Arg II.
A representative Western blot membrane presented in Figure 4a shows increased expression of
Arg I and, to a lesser extent, Arg II in MCT-treated compared to sham-treated control rats.
Semi-quantitative analysis revealed a significantly increased expression in the MCT compared to
the control group both for Arg I (22.7 fold; p = 0.001; Figure 4b,d) and for Arg II (5.1-fold; p = 0.004;
Figure 4c,d).
Treatment effects of the Arg inhibitor nor-NOHA in MCT induced pulmonary hypertension.
2.4. Haemodynamics
When comparing the RVPsys values in the three different experimental groups, a significant
increase in RVPsys in the MCT (RVPsys = 81.14 ± 16.65 mmHg; heart rate = 325 ± 22 bpm) compared
to the control (RVPsys = 41.2 ± 15.86 mmHg; heart rate = 308 ± 29 bpm) group could be demonstrated
(p = 0.002). In the MCT/nor-NOHA (RVPsys = 52.09 ± 19.10 mmHg; heart rate = 310 ± 14 bpm) group,
RVPsys were significantly decreased compared to the MCT group (p = 0.006) and did not differ from
that of the sham-treated control group (p = 0.275) (Figure 5a). There were no significant differences
with respect to the heart rate of the animals in the three experimental groups (p = 0.123).
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Figure 4. Western Blot and semi-quantitative analysis of Arginase I and II expression in PH rats
(MCT group, p = 8) compared to controls (p = 9): (a) representative Western Blot experiment showing
increased expression of arginase I and arginase II in MCT treated compared to sham-treated control
rats (β-actin served as housekeeping protein); (b–d) software-based densitometric semi-quantitative
analysis of arginase I and II expression normalized to β-actin. Data are presented as means and SD.
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Figure 5. (a) Comparison of haemodynamic treatment effects of the Arginase inhibitor nor-NOHA:
significant increase of RVPsys values in the MCT compared to the control group (p = 0.002), decreased
RVPsys values in the MCT/nor-NOHA compared to the MCT group (p = 0.006) and non-significantly
elevated RVPsys values between the MCT/NorNoha and the sham-treated control group (p = 0.275).
Data are presented as means and SD; (b) comparison of treatment effects of the Arginase inhibitor
nor-NOHA with respect to lung tissue remodelling: the sham-treated control group showed healthy
lung tissue, the MCT group exhibited distinct signs of lung damage (p < 0.001 compared to the control
group), which were diminished in the MCT/nor-NOHA group (p = 0.022 compared to the MCT group).
Data are presented as means and SD.
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2.5. Histological Evaluation of Lung Tissue Remodeling Using a Sum-Score System
The sham-treated control group showed healthy lung tissue (sum-score 1.59 ± 1.56), the MCT
group exhibited distinct signs of lung damage (sum-score 8.17± 2.42; p < 0.001 compared to the control
group), which were diminished in the MCT/nor-NOHA group (sum-score 5.77 ± 1.42; p = 0.022
compared to the MCT group) as shown in Figure 5b.
3. Discussion
The current study was focused on the investigation of the differential protein expression of the
Arg isoforms I and II in the rat model of MCT induced PH and to evaluate the effect of the Arg
inhibitor nor-NOHA. The animal model was chosen because it is, besides models of hypoxia induced
PH, a well-established model, which has been used for a long time to investigate PH both, in terms of
mechanistic studies as well as preclinical testing of novel treatment strategies. As for any other PH
animal model available, it has several limitations and some concerns should be kept in mind when
interpreting the results obtained with this model [32,33]. Against the background of the fact that
most studies investigating the role of Arg in PH development as well as effects of enzyme inhibition
were performed using models of hypoxia induced PH [19,20,28,35], it is of certain scientific interest to
elucidate these processes in the MCT model as performed in the current study. Protein expression and
tissue distribution analysis clearly showed an increased expression of both, Arg I and Arg II in induced
PH compared to controls. Both enzymes revealed typical and distinguishable spatial associations
to several lung tissue components or certain cell types. The obtained results mainly go in line with
the findings of Choi and co-workers who described tissue expression of Arg I and Arg II in healthy
rat organs in a sophisticated way in Sprague–Dawley rats, the same strain as used in this study for
the MCT model [34]. On the quantitative level, the current study could show that there is a relevant
increase in protein expression of both, Arg I and Arg II. While for Arg II, a 5.1-fold increase was
observable, Arg I revealed a 22.7-fold increase. The finding is novel and its discussion against the
background of the available literature is challenging due to most in vivo studies in animal models,
predominantly models of hypoxia induced PH, focusing on Arg II, while not comparatively looking
for Arg I or even differentiating between the isoforms [12,18–22,29,36]. This might be for the following
reasons: first, Arg isoform expression depends on both, the species used for an animal model as
well as the pathologic stimulus leading to Arg up-regulation (reviewed in [7]). Second, in human
PAH, Arg II seems to be of predominant significance compared to Arg I at least when referring to
the available studies, which are hitherto rare [26,27]. For those reasons, especially species specificity
of Arg isoform expression might explain our current findings in the rat model. For a variety of cell
types, in particular smooth muscle cells and endothelial cells, it could be evidenced that Arg I is the
predominantly expressed isoform in rats [8,9,37,38] whereas it is Arg II in humans [12,14,36,39–42].
In correspondence with our finding concerning a certain role of Arg I in induced PH, Cowburn
and co-workers observed a HIF2α enhancement triggered by chronic hypoxia in a mouse model
resulting in an up-regulation of its downstream target Arg I with the consequence of a dysregulated
NO homeostasis [28]. There are only few in vivo studies dealing with the impact of Arg in rat models
of PH [19,21,22,35]. From these, only one study used the MCT model [22], two studies used hypoxia
as pathologic stimulus [19,35] and one study bleomycin [21]. Neither of these studies discriminated
between Arg isoforms. Taken together the findings of the first part of our study it has to be noted that
in the MCT rat model of PH Arg I is the predominantly expressed isoform. This is likely at least in part
due to species-specific aspects. The question if there is a specific functional reason for Arg I instead of
Arg II must be the objective of further studies.
By treatment with the non-selective Arg inhibitor nor-NOHA, we could show two main effects:
first, a significant reduction of RVPsys to levels of untreated controls and second, a reverse lung tissue
remodelling. Against the background of Arg isoform expression analysis we hypothesize that these
effects are mediated by Arg I inhibition. But, since also Arg II was mildly upregulated in our model,
Int. J. Mol. Sci. 2017, 18, 1609 8 of 13
only a selective Arg inhibitor would definitely answer the question, which isoform truly mediates
therapy response. Unfortunately, such an inhibitor is not available by now.
The data obtained in this study clearly demonstrate a reduction of RVPsys measured invasively
by Arg inhibition. This finding goes in line with the observations of Nara and co-workers
showing a reduction of hypoxia induced PH in response to Arg inhibition using nor-NOHA [19].
Similar results could be obtained by Jiang and co-workers [35]. By applying the Arg inhibitor
amino-2-borono-6-hexanoic acid, bleomycin induced PH could be prevented in a further study in
neonatal rats [21]. A very interesting recent study focused on the effects of Arg inhibition in a mouse
model of sickle cell disease and could clearly show a reversal of endothelial dysfunction, vascular
stiffness and PH by improving NO bioavailability [43].
In summary of our results and the limited number of studies available from the literature, Arg
inhibition seems to be a promising novel strategy in the prevention or treatment not only of group 1 PH
(PAH) but likely also in other groups, in particular group 3 (lung disease or hypoxia associated PH).
To our very best knowledge, this is the first study that investigated the effects of Arg inhibition in
lung tissue remodelling in PH. We used a sum-score system comprising all relevant features of PH
associated lung alterations on the histological level including pulmonary vascular remodelling. This
scoring system has been recently developed by our group [44]. As described above, nor-NOHA
treatment (MCT/nor-NOHA group) resulted in a significant reduction of the sum-score levels
compared to the MCT group. Although not applying a detailed lung tissue remodelling score,
there are some recent studies demonstrating positive effects of Arg inhibition on pulmonary artery
remodelling and smooth muscle cell proliferation, which goes in line with our current findings. Thus,
we hypothesize that, besides haemodynamic effects, also a reverse lung tissue and pulmonary vascular
remodelling is initiated by Arg inhibition possibly leading to disease reversal also on the causative
level. This would certainly be of great clinical impact and should therefore necessarily be the subject of
further functional studies.
4. Material and Methods
4.1. Animal Model of Induced Pulmonary Hypertension and Treatment Protocol
Sprague–Dawley rats (200–250 g) were obtained from Charles River (Sulzfeld, Germany) and
allowed to acclimatize for 7 days with ad libitum access to food and water and exposure to
controlled light/dark cycles before starting experiments. All experiments were carried out in
accordance to the National Institute of Health Guidelines for the Care and Use of Laboratory
Animals (8th edition; available online: https://www.ncbi.nlm.nih.gov/books/NBK54050/) and to
the European Community Council Directive for the Care and Use of Laboratory Animals of 22
September 2010 (2010/63/EU; available online: http://ec.europa.eu/environment/chemicals/lab_
animals/legislation_en.htm). The study protocol was approved by the appropriate State Office of
Food Safety and Consumer Protection (TLLV, Bad Langensalza, Germany; local registration number
(identification code): 02-004/14, approval date: 14 March 2014).
The 35 rats were divided into three experimental groups: 11 rats were injected with NaCl (300 µL)
subcutaneously and were used as controls (control group), 11 rats were treated with monocrotalin
(MCT, Carl Roth, Karlsruhe, Germany) alone to induce PH (MCT group) and 13 rats were treated with
MCT followed by a treatment with the non-selective arginase inhibitor Nω-hydroxy-nor-L-arginine
(nor-NOHA; Bachem, Bubendorf, Switzerland) (MCT/nor-NOHA group). MCT was administered by
subcutaneous injection of a single dose of 60 mg/kg body weight in a volume of 300 µL. Nor-NOHA
was administered by intra-peritoneal injection in a dose of 100 mg/kg body weight once daily from
day 14 to day 28 post injectionem (p.i.) For the prevention of secondary infections or inflammatory
lung-alteration, rats received Enrofloxacin (Baytril, WDT, Garbsen, Germany) 2.5% ad water from day
2 to 15. On day 28 p.i., rats were anaesthetized intraperitoneally and haemodynamic measurements
were performed as described below directly before rats were sacrificed in deep anaesthesia and
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analgesia. Organs were excised and immediately shock frozen in liquid nitrogen and stored at
−80 ◦C or formalin-fixed and paraffin-embedded until further analysis. To carefully monitor clinical
well-being of the animals, rats were weighed and examined daily and the state of health was evaluated
by applying a clinical severity score (CSS). This score estimates the following five parameters and
ranges from 1 to 5 for each of them: weight development; spontaneous activity; reaction to exogenous
stimuli, posture / social behavior and breathing (1 = no signs of illness; 2 = low-grade impairment;
3 = mild-grade impairment; 4 = high grade impairment; 5 = dead).
4.2. Haemodynamic Measurements
Right heart catheterization (RHC) was performed using a 1.4F micro conductance pressure-volume
catheter (model SPR-839; Millar Instruments Inc, Houston, TX, USA) inserted via the right jugular vein.
Right ventricular blood pressure and, if technically feasible, also pulmonary arterial blood pressure
traces were continuously registered in closed chest animals. Analysis of pressure curves was performed
using a PowerLab system (ADInstruments Ltd., Sydney, Australia) connected to the catheter.
4.3. Histological Evaluation
A total of 4 µm sections of the formalin-fixed and paraffin-embedded lung tissue were subjected
to H&E-staining (HE). Analysis of the extent of lung tissue damage was performed using a sum-score
system (ranging from 0 to 12 points) including the most relevant histopathological features occurring
in PH, namely atelectasis area, emphysema area, media hypertrophy of peribronchial arteries,
perivascular cellular edema of peribronchial arteries and media hypertrophy of small arteries as
described by our group recently. In detail, the semi-quantitative score was assessed as follows:
parameter 1 = atelectasis area (area in % of atelectasis related to total area of tissue section): not
detectable = 0 points, <30% = 1 point, ≥30% = 2 points; parameter 2 = emphysema area (area in
% of emphysema related to total area of tissue section): not detectable = 0 points, <30% = 1 point,
≥30% = 2 points; parameter 3 = media hypertrophy of peribronchial arteries (cellular hypertrophy
of the tunica media of arteries spatially associated to bronchial structures): not detectable = 0 points,
weak = 1 point, moderate = 2 points, severe = 3 points; parameter 4 = perivascular cellular edema
of peribronchial arteries (cellular edema locates in the perivascular region around peribronchial
arteries): not detectable = 0 points, detectable = 2 points; parameter = media hypertrophy of small
arteries (cellular hypertrophy of the tunica media of small arteries showing no spatial association to
bronchial structures): not detectable = 0 points, weak = 1 point, moderate = 2 points, severe = 3 points.
The maximum sum-score value is 12 points [44].
4.4. Immunohistochemistry
For immunohistochemical detection of Arg I and Arg II, 4 µm sections of
formalin-fixed/paraffin-embedded lung tissue were deparaffinized and subjected to antigen-retrieval
with citrate-buffer (pH 9.0) for 30 min heated to 95 ◦C. Non-specific staining due to endogenous biotin
was inhibited by applying the Dako Biotin Blocking System (Dako Deutschland GmbH, Hamburg,
Germany). Arg I antibody (dilution 1:100; clone H-52, rabbit polyclonal antibody, Santa Cruz
Biotechnology, Dallas, TX, USA) and Arg II antibody (dilution 1:125; clone H-64, rabbit polyclonal
antibody, Santa Cruz Biotechnology, Dallas, TX, USA) were applied over night at 4 ◦C. In the next
step, sections were incubated with a biotin-conjugated donkey anti- rabbit antibody (1:200, Jackson
ImmunoResarch, West Grove, Chester County, PA, USA) and furthermore with an AP-conjugated
streptavidin-biotin-antibody(1:75, SouthernBiotech, Birmingham, AL, USA). Detection of bound
antibodies was then performed using the Chromogens of the DAKO-Real Detection System (AP/Red;
Dako Deutschland GmbH, Hamburg, Germany). Immunostained sections were counterstained with
haematoxylin. As negative control, the antibodies were replaced by nonimmune serum.
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4.5. Protein Isolation and Western Blotting
Proteins were isolated from shock frozen lung tissue. After tissue maceration in liquid nitrogen,
triton lysis buffer (50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.5,
150 mM NaCl, 1.5 mM MgCl2, 1 mM Ethylenediaminetetraacetic acid (EDTA), 1% Tritonx 100, 1%
Sodiumdeoxychoacid, 0.1% Sodium dodecyl sulfate (SDS), 10% glycin, 10 mM Sodiumpyrophosphate,
1 mM 1,4-Dithiothreitol (DTT) containing a protease inhibitor cocktail (complete ULTRA Tablets; Roche
Diagnostics GmbH, Mannheim, Germany) was added (100 mg tissue/1 mL lysis buffer) and allowed
to incubate for 30 min on ice. In a next step, lysates were centrifuged at 14,000 rpm for 20 min at 4 ◦C.
The supernatant was transferred to new tubes and protein concentration was determined by the Pierce
BCA Protein-Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA). Samples of the supernatants
(controls and monocrotalin-treated rats) containing 20 µg protein were diluted 1:2 in loading buffer
and used for SDS-PAGE. After electrophoresis, proteins were transferred to a polyvinylidene difluoride
membrane and blocked for 1 h in TBS/0.1% Tween (TBS-T) containing 5% nonfat dried milk.
Membranes were then assayed for β-actin (dilution 1:1000, clone C4, mouse monoclonal antibody,
Merck Millipore, Billerica, MA, USA) as housekeeping protein and Arg I (dilution: 1:100, clone
19/Arginase I, mouse monoclonal antibody, BD Transduction Laboratories, Franklin Lakes, NJ, USA)
and Arg II (dilution 1:100, clone C-3, mouse monoclonal antibody, Santa Cruz Biotechnology, Dallas,
TX, USA). The membranes were incubated with the primary antibodies overnight at 4 ◦C, washed
three times with TBS-T, and subsequently treated with a peroxidase conjugated donkey-anti-mouse
IgG secondary-antibody (Jackson Immuno Research Lab., West Grove, PA, USA) for 1 h at room
temperature. After washing with TBS-T, the protein bands were visualized by chemiluminescence
(BM Chemiluminescence Western Blotting Kit (mouse/rabbit), Roche Diagnostics GmbH, Mannheim,
Germany) and quantified by densitometry analysis using the ImageJ software, (National Institutes for
health (NIH), available online: http://rsb.info.nih.gov/ij/download.html).
4.6. Statistics
Statistical analyses were performed with IBM SPSS statistics, version 22.0 (IBM Inc., North Castle,
NY, USA). Data are expressed as mean ± standard deviation (SD). Kruskal-Wallis Test was used
to test for significant differences between different experimental groups. A p-value < 0.05 defined
statistical significance.
5. Conclusions
We could provide novel data concerning the role of Arg isoforms and Arg inhibition in an
appropriate animal model of PH. Besides a striking reduction of RVPsys, we could show for the first
time that Arg inhibition partially reverses lung tissue remodeling. Integration of our findings and
further recent studies leads to the suggestion that this novel treatment strategy might not only be
promising for group 1 but also for other groups of PH, for which there are no specific therapy options
available until now.
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